The integration of PI3K inhibition with ICB, particularly PD‐1 blocking, demonstrates the potential to enhance antitumor immunity by selectively depleting intratumoral Tregs and increasing the population of tumor antigen‐specific CD8+ T cells, suggesting a promising strategy for optimizing cancer treatment. Here, PIK3CB is linked to cancer.